NTpharma

NTpharma is a pioneering biopharmaceutical company founded in 2011. Specializing in the GMP production of nanovaccines and biopharmaceuticals with carbohydrate binders, the company's slogan "Delivering next-generation nanovaccines and biopharmaceuticals faster for global health protection" encapsulates its mission. NTpharma has received a Venture Round investment from RUSNANO on 28 July 2009. The company is focused on constructing a state-of-the-art facility in Pereslavl’-Zalessky, approximately 150 kilometers northeast of Moscow, dedicated to the manufacturing of vaccines and pharmaceuticals. Their efforts are geared towards producing next-generation vaccines, including a polyvalent human flu vaccine, and developing pharmaceuticals for detoxification in oncological therapy and treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig’s disease). NTpharma's groundbreaking technology has significantly reduced the time needed for culturing and producing vaccines, providing a crucial advantage in addressing rapidly spreading pandemic flu strains. The company operates within the realms of Biopharma, Biotechnology, Health Care, and Manufacturing.